Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by chrispion Apr 20, 2022 9:44am
191 Views
Post# 34616014

RE:RE:Fierce biotech

RE:RE:Fierce biotech
LOOPA441 wrote: Neither party has shared the financial terms of the deal. Bioasis flagged up financial difficulties at the start of the year, warning investors of “a material uncertainty that may raise significant doubt about [its] ability to continue as a going concern.” At that time, Bioasis said it had enough cash to fund its operation “through approximately May 2022.”


As KayakerBC already mentioned, this is standard operating boilerplate language when a company has less than one year of operating funds on the books. I've seen it a million times in many small companies.
Anyways, astute readers (all those who aren't trolls ;) on this board will know that they still have a $7m USD line of credit with Lind that they can withdraw from at their choosing of time and amount. Imo this was always a backstop to ensure good faith bargaining with partners in licensing deals which we are all eagerly anticipating coming in the weeks and months ahead so there will be no need to drawn down from the LOC.
<< Previous
Bullboard Posts
Next >>